Drug intelligence / Profile preview

AT-018

Development stage: Preclinical
Lead developer: Asieris Pharmaceuticals

Overview

AT-018 is a preclinical drug candidate being developed by Asieris Pharmaceuticals for the treatment of ovarian cancer and breast cancer. The drug was discovered using Asieris' proprietary Target-based AI-Driven Drug Discovery (TAIDD) platform, which utilizes artificial intelligence to streamline the preclinical drug discovery process. As part of Asieris' oncology and women's health portfolio, AT-018 represents an expansion into gynecological malignancies. As of current public disclosures, the specific biological target and therapeutic modality of AT-018 remain undisclosed by the developer.

Beyond the preview

Go deeper on AT-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-018.

Explore the full profile